ABSTRACT
Objective: To analyze the clinicopathological characteristics, treatment and prognosis of Luminal B-like breast cancer in pT1N0M0 stage. Methods: The data of 300 patients with stage pT1N0M0 Luminal B-like breast cancer who underwent surgery in Tianjin Medical University Cancer Institute and Hospital from January 2010 to January 2013 were collected. The clinicopathological characteristics, treatment and prognosis were retrospectively analyzed by using the statistical methods such as χ2 test, univariate analysis, COX multivariate analysis, Kaplan-Meier and so on. Results: In 300 cases of breast cancer, there were 24 cases (8%) in pT1aN0M0 stage, 115 cases (38.3%) in pT1bN0M0 stage, and 161 cases (53.7%) in pT1cN0M0 stage. Intergroup analysis (χ2 test) showed that only histological grade was related to tumor size (P = 0.004). Univariate analysis showed that age, histological grade, human epidermal growth factor receptor-2 (HER-2) expression, Ki-67 expression and chemotherapy had an effect on the five-year disease-free survival (DFS) of patients (all P 0.05). For the patients in pT1cN0M0, the five-year DFS rate in taxane combined with anthracycline chemotherapy group was significantly higher than that in taxane/anthracycline alone chemotherapy group (P = 0.042), but the five-year OS rate was not significant different between the two groups (P = 0.711). Conclusion: Postoperative adjuvant chemotherapy can improve the prognosis of patients with stage pT1N0M0 Luminal B-like breast cancer. The patients in pT1a-bN0M0 stage may be given taxanes/anthraquinones chemotherapy for reducing overtreatment. For the patients in pT1cN0M0 stage, the prognosis will be better when the taxane combined with anthracycline chemotherapy is given.
ABSTRACT
Objective To investigate the risk factors for the occurrence of cerebral infarction in patients with capsular warning syndrome (CWS). Methods Consecutive patients with transient ischemic attack (TIA) meeting the CWS clinical manifestations were col ected retrospectively. They were divided into either a cerebral infarction group or a non-cerebral infarction group according to the brain diffusion weighted imaging findings. The independent risk factors for patients with CWS were identified through the comparison of demographic and baseline clinical data. Results A total of 39 patients were enrol ed, including 25 males (64. 1%) and 14 females (35. 9%), and their mean age was 58. 9 ± 10. 3 years. There were 21 patients in the cerebral infarction group and 18 in the non-cerebral infarction group. Compared with the non-cerebral infarction group, the age of patients in the cerebral infarction group was older (62. 5 ± 9. 3 years vs. 54. 8 ± 10. 2 years;t=2. 470, P=0. 018). The constituent ratio of the patients with a history of previous stroke or transient ischemic attack was higher (33. 3% vs. 5. 6%; P=0. 049), the fasting blood glucose level was higher (8. 2 ± 3. 2 mmol/L vs. 6. 0 ± 1. 3 mmol/L; t=2. 748, P=0. 009), and ABCD2 score was higher (5. 2 ± 1. 1 vs. 3. 5 ± 1. 1;t=4. 734, P<0. 001). Multivariate logistic regression analysis showed that the ABCD2 score was an independent risk factor for cerebral infarction in patients with CWS (odds ratio, 4. 529, 95% confidence interval 1. 233-16. 627;P=0. 023). Conclusions The higher ABCD2 score was an independent risk factor for the occurrence of cerebral infarction in patients with CWS. It can be used as an evaluation tool for predicting the risk of cerebral infarction in patients with CWS.